V-01

V-01
Vaccine description
TargetSARS-CoV-2
Vaccine typeProtein subunit
Clinical data
Routes of
administration		Intramuscular

V-01 is a COVID-19 vaccine candidate developed by a subsidiary of Livzon Pharmaceutical Group Inc.[1][2][3]

References

  1. ↑ "China approves clinical trials for Livzon Pharma unit's COVID-19 vaccine". Reuters. 23 March 2021. Retrieved 21 April 2021.
  2. ↑ "评价重组新型冠状病毒融合蛋白疫苗在健康人群免疫原性和安全性随机、双盲、安慰剂对照的II期临床试验". chictr.org.cn. Chinese Clinical Trial Registry. Retrieved 21 April 2021.{{cite web}}: CS1 maint: url-status (link)
  3. ↑ "评价重组新型冠状病毒融合蛋白疫苗在健康人群安全性和免疫原性随机、双盲、安慰剂对照的I期临床试验". chictr.org.cn. Chinese Clinical Trial Registry. Retrieved 21 April 2021.{{cite web}}: CS1 maint: url-status (link)
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.